- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03294434
Predicting Sites of Tumour Progression in the Invasive Margin of Glioblastomas (PRaM-GBM Study) (PRaM-GBM)
Brain tumours are the leading cause of cancer deaths in children, men under the age of 45 and women under the age of 25. Glioblastoma is the most common and most malignant primary tumour. The predominant treatment is surgical removal of the tumour followed by radiotherapy. Sadly the majority of patients given this treatment develop recurrent and progressive disease.
Better understanding of the invasive margin might improve outcomes by facilitating more complete surgical resection beyond the traditional contrast enhancing margins. Diffusion tensor MRI (DTI) is an imaging technique which may be able to predict the site of tumour recurrence. DTI has previously been shown to identify regions, which have been confirmed with biopsies, to be areas of invasive tumours and are present before progression is seen with an MRI.
The primary aim of this study is to qualify an imaging biomarker that can be applied at initial presentation, that can accurately predict the site of where glioblastomas will progress after treatment and allow personalisation of both radiotherapy and surgical targets.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a multicentre, prospective longitudinal observational cohort study in patients with high grade glioma, who have surgery planned to remove >90% of the tumour, and subsequent radical radiotherapy with concomitant tomozolomide. The purpose of this study is to establish a model using DTI that can accurately predict the site of where glioblastomas will progress after treatment. This study aims to validate the use of DTI as a biomarker across multiple centres to develop analysis methods that could be used in the future to personalise radiotherapy treatment volumes, and potentially surgical targets.
Patients will be given a DTI-MRI both prior to the operation and prior to radiotherapy. Clinical MRIs will take place according to standard guidelines. Whilst the study is open patients will participate in the study until death. Once a total of 70 patients from the first 90 have shown true progression patients will participate in the study for a minimum of 6 months from the beginning of radiotherapy.
This study will be conducted in 6-10 NHS centres, where 120 patients will be recruited, patients who are withdrawn will be replaced.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Cambridge, United Kingdom, CB2 0QQ
- Cambridge University Hospitals NHS Foundation Trust
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Have given written informed consent to participate
- Assessed by a neuroscience MDT to have a high grade glioma on imaging, OR if in the opinion of the CI, with guidance from the local PI that all relevant and appropriate members of a multidisciplinary team agree a high grade glioma diagnosis;
- Considered suitable for radical radiotherapy (60 Gy) with concomitant chemotherapy (Stupp Regime);
- WHO PS 0 or 1 (see Appendix 3);
- Age ≥16;
- Patient suitable for tumour resection where the treating neurosurgeon feels that >90% of the enhancing tumour will be resected;
Exclusion Criteria:
- Patients who are participating in trials involving investigational treatments
- Patients who are unsuitable for a contrast-enhanced MRI will be excluded. Such clinical problems include, but are not limited to:
- MR unsafe metallic implants;
- Claustrophobia;
- Allergy to gadolinium contrast agent;
- History of severe renal impairment.
- Patients unable to provide written informed consent
- PET sub-study only: Pregnant women
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
High Grade Glioma
Diffusion tensor Imaging (DTI-MRI) scan to be performed pre-operatively and pre-radiotherapy
|
Diffusion tensor Imaging (DTI) is a technique sensitive to the ordered diffusion of water along white matter tracts and can detect subtle disruption.
A diffusion tensor signature method was developed that splits the tensor information into isotropic and anisotropic diffusion components.
This can differentiate regions of pure tumour from invaded white matter.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Site of glioblastoma true progression correctly predicted by DTI scan
Time Frame: 18 months
|
Assess the diagnostic accuracy of DTI at pre-surgery or/and pre-radiotherapy as a biomarker to predict site of glioblastoma progression
|
18 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Accuracy of DTI as a biomarker
Time Frame: 18 months
|
Explore difference of DTI performed pre-surgery and pre-radiotherapy to predict the site of glioblastoma progression
|
18 months
|
Perfusion imaging
Time Frame: 18 months
|
Investigate dynamic susceptibility imaging to measure rCBV of the invasive margin to improve the accuracy of the DTI biomarker.
|
18 months
|
Time to progression
Time Frame: 18 months
|
Investigate if pattern of invasion can predict time to progression
|
18 months
|
Extent of resection and volume of tumour that remains post-surgery by standard imaging and DTI
Time Frame: 18 months
|
Determine the effect of resection on the invasive margin as determined by DTI
|
18 months
|
Radiotherapy dose according to DTI-defined invasive region
Time Frame: 18 months
|
Retrospectively compare dose of radiotherapy using the DTI-defined invasive region receives with conventional radiotherapy plans
|
18 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Difference of area highlighted by amino-acid PET and DTI-MRI
Time Frame: 18 months
|
Investigate the relationship between amino-acid PET, area of surgical resection and the area highlighted by DTI-MRI
|
18 months
|
Number of amino-acid PET only image guided biopsies taken from patients
Time Frame: 18 months
|
Investigate the feasibility of taking image-guided biopsies from patients in the region outside of the area with increased amino-acid PET uptake
|
18 months
|
Site of glioblastoma true progression correctly predicted from pre-operative imaging by a region that is predicted by the DTI abnormality outside of the area of increased uptake to amino-acid on PET
Time Frame: 18 months
|
Explore the extent of invasive disease (from DTI/perfusion) that is likely to be left following surgery by assessing potential resected tumour using amino acid PET
|
18 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Stephen Price, Cambridge University Hospitals NHS Foundation Trust
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PRaM-GBM
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on High Grade Glioma
-
James FelkerConnor's Cure; Ellie Kavalieros Fund; Translational Brain Tumor Research FundActive, not recruitingNewly Diagnosed Pediatric Pontine Glioma | Newly Diagnosed Pediatric High Grade Glioma | Recurrent Pediatric High Grade Glioma | Recurrent Pediatric Low Grade GliomaUnited States
-
National Cancer Institute (NCI)RecruitingGlioma | High Grade Glioma | Malignant Glioma | Gliomas | Low Grade GliomaUnited States
-
Maastricht Radiation OncologyMaastricht University Medical Center; Ziekenhuis Oost-Limburg; Zuyderland Medisch...Active, not recruitingHigh Grade Glioma | Low-grade GliomaNetherlands
-
The University of Texas Health Science Center at...CompletedHIGH GRADE GLIOMAUnited States
-
Hospital del Río HortegaCompletedGlioma | Glioblastoma | Low-grade Glioma | Glioma, Malignant | High-grade GliomaSpain
-
Hospices Civils de LyonTerminatedLow Grade Glioma (LGG), High Grade Glioma (HGG)France
-
Hospices Civils de LyonCompletedLow Grade Glioma (LGG) | High Grade Glioma (HGG)France
-
University of California, San FranciscoNovartis Pharmaceuticals; Pediatric Brain Tumor Foundation; The Lilabean Foundation...RecruitingHigh Grade Glioma | Low-grade Glioma | Recurrent World Health Organization (WHO) Grade II GliomaUnited States
-
BioMimetix JV, LLCNational Cancer Institute (NCI); Duke Cancer InstituteActive, not recruitingGlioblastoma | High Grade Glioma | Astrocytoma, Grade IIIUnited States
-
Pediatric Brain Tumor ConsortiumNational Cancer Institute (NCI); Treovir, LLC; American Lebanese Syrian Associated...Not yet recruitingNeoplasms | Malignant Glioma of Brain | Glioblastoma Multiforme | High Grade Glioma | Giant Cell Glioblastoma | High-grade Glioma | Anaplastic Astrocytoma of Brain | Anaplastic GliomaUnited States
Clinical Trials on Diffusion tensor Imaging (DTI)
-
The Hospital for Sick ChildrenCompletedPartial Epilepsy | Localization-related EpilepsyCanada
-
Second Affiliated Hospital, School of Medicine,...RecruitingANCA Associated VasculitisChina
-
Washington University School of MedicineCompletedUterine Cervical NeoplasmsUnited States
-
University of Michigan Rogel Cancer CenterTerminated
-
University of MichiganWithdrawn
-
Swiss Paraplegic Research, NottwilCompletedParalysis | Functional Neurological Symptom Disorder | Conversion Disorder With Weakness/ParalysisSwitzerland
-
Assistance Publique - Hôpitaux de ParisCompletedCervical SpondylosisFrance
-
University of ArizonaNational Cancer Institute (NCI)CompletedBreast Cancer | Breast Carcinoma | Neuropathy | Neuropathy;PeripheralUnited States